From heparins to factor Xa inhibitors and beyond.

  title={From heparins to factor Xa inhibitors and beyond.},
  author={Susanne Alban},
  journal={European journal of clinical investigation},
  volume={35 Suppl 1},
  • Susanne Alban
  • Published 2005 in European journal of clinical investigation
Despite some disadvantages, unfractionated heparin (UFH) and oral anticoagulants have been the only anticoagulants for prophylaxis and therapy of thromboembolic disorders for several decades. Based on the increasing knowledge of the structure and pharmacology of heparin, low molecular weight heparins (LMWH) have been developed in the 1980s. Compared to UFH, their advantages are mainly based on their reduced nonspecific binding to proteins and cells resulting in improved pharmacokinetics. In… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 18 extracted citations

Blood coagulation factor Xa as an emerging drug target.

Expert opinion on therapeutic targets • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…